Loading...
XSHE
300267
Market cap1.11bUSD
Dec 05, Last price  
3.79CNY
1D
-0.26%
1Q
0.00%
Jan 2017
-70.96%
IPO
73.44%
Name

Hunan Er-Kang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300267 chart
P/E
—
P/S
6.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-16.12%
Revenues
1.14b
-36.09%
126,132,271157,832,491363,933,848608,416,476834,858,6441,010,838,0171,370,358,4911,737,940,0352,705,821,6232,827,885,1902,354,485,5792,744,341,0052,382,275,0102,235,302,7871,870,540,8101,783,118,7801,139,612,276
Net income
-373m
L+91.16%
10,844,11322,750,49066,462,150117,811,939151,906,924192,929,449288,288,645588,718,936795,403,732522,456,311216,579,339161,530,199192,306,417045,944,930-195,322,353-373,371,435
CFO
167m
+12.31%
209,79810,181,90742,471,66475,733,19284,021,539174,221,200175,382,420518,955,781486,495,536687,211,143123,894,781445,815,848178,527,34192,683,406281,019,942148,420,737166,691,706
Dividend
Jun 09, 20230.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate and its series products. The company was founded in 2003 and is based in Liuyang, China.
URL
https://www.hnerkang.com/
IPO date
Sep 27, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT